In Kfar Saba Medical Center, Israel is undergoing clinical trial "Study to evaluate the safety, tolerability and efficacy of cannabidiol (CBD) as a steroid-sparing therapy in patients with chronic spontaneous urticaria (CSU)" CBD dosage will start at 25 mg twice daily and will increase once every 14 days, unless side effects are observed, up to 50 mg twice a day, 100 mg twice a day, and finally up to 150 mg twice a day CBD, respectively. The reception will be with meals.

Study Objectives To stop steroid use and continue with CBD only. Laboratory tests will be done at baseline and then monthly until the end of the study.